Glenmark files arbitration claim against Napo over crofelemer rights
This article was originally published in Scrip
Executive Summary
Glenmark has filed a 'statement of claim' with the American Arbitration Association against Napo Pharmaceuticals aimed at safeguarding its exclusive rights to Napo's anti-secretary gastrointestinal agent, crofelemer, in certain countries.